Description
Tofacitinib is an inhibitor of JAK1/2/3 that is clinically used to treat myelofibrosis and rheumatoid arthritis. Tofacitinib exhibits immunosuppressive, anti-inflammatory, and antiviral activities. In vitro, tofacitinib inhibits production of inflammatory cytokines, Th2 cell differentiation, Th17 cell differentiation, and activation of STAT1, which in turn prevents induction of T-bet and generation of Th1 cells. In other cellular models, tofacitinib inhibits HIV replication and reactivation of latent HIV-1.